Vertical: HealthcareBase Year: 2018
Market Size (2018)
$4.77B
Projected (2025)
$9.44B
CAGR (2016–2025)
10.5%
Key Players
10+
Botulinum toxin is an exotoxin released by the organism Clostridium botulinum responsible for the deadly poisoning condition known as botulism. It is one of the deadliest toxins on earth. The botulinum neurotoxins include eight distinct subtypes identified as A, B, C1, C2, D, E, F, and G. Botulinum toxin is widely preferred as an effective mode of treatment across cosmetic and various therapeutic indications such as spasticity, cervical dystonia, and chronic migraine etc.
The rising cases of spasticity, cervical dystonia, and chronic migraine, growing demand for facial aesthetics, and increasing product launches and approvals by key players are expected to drive the growth of the botulinum toxin market. However, adverse effects associated with botulinum toxin and poor reimbursement policies are expected to hamper the market growth during the forecast period.
The Botulinum Toxin Market market is projected to grow at a CAGR of 10.5% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global botulinum toxin market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on type, application, end user and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global botulinum toxin market is profitable, both for existing players as well as new entrants. A substantial level of rivalry is observed among the existing manufacturers in the market. Our analysis revealed that market players have adopted different strategies and innovative research and development techniques to expand their business and secure their position in the global botulinum toxin market. In recent years, strategic movements by major players included approvals, which have been used as market penetration strategies and a means to reduce competition.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on geographical expansion and product improvement. It has also been predicted that improvement of the global economic scenario, combined with efforts to enhance infrastructure, can fuel market growth, making it an ideal time to launch new products and increase the market presence.
Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies to stay abreast of emerging technologies that could affect the continuing competitiveness of their product lines in the market.
The top players in the global botulinum toxin market are Allergan, Ipsen Pharma/Galderma S.A., and Merz Pharma.
Allergan, a leading pharmaceutical company, based in the US, manufactures products for areas such as ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, and urological diseases. The company has a strong product portfolio in the market. Also, the company has a vast geographic reach. This prominent player is involved in various activities, such as collaborations with regional vendors as well as key players operating in the botulinum toxin market. The company has also successfully integrated small companies through mergers and acquisitions to build a strong supply chain network. The company has captured 75.3% of the global market share in 2018.
Ipsen Pharma and Galderma SA accounted for the second-largest market share of 10.3% in 2018. It operates in endocrinology, oncology, neurology, cognitive disorders, gastroenterology, and rheumatology areas. The company has a strong research and development unit which offers innovative products.
Merz Pharma GmbH & Co KGaA operates through the following segments, namely, neurology, over the counter (OTC) medicine, dietary supplements, and skincare products. The company accounted for 7% of the total botulinum toxin market share in 2018.
Other prominent players operating in the market are Daewoong Pharmaceutical Co., Ltd, US WorldMeds, LLC, Evolus, Inc., Hugel, Inc., and Medytox. The majority of the companies are working in collaboration with local players to distribute their products in the market. Moreover, companies such as Revance Therapeutics, Inc. are developing innovative products that are likely to hit the market in the next 3 to 5 years. After product approval of core products, Revance Therapeutics, Inc. is anticipated to capture the significant market share of the global botulinum toxin market.
The top players in the global botulinum toxin market are Allergan, Ipsen Pharma/Galderma S.A., and Merz Pharma.
Allergan, a leading pharmaceutical company, based in the US, manufactures products for areas such as ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, and urological diseases. The company has a strong product portfolio in the market. Also, the company has a vast geographic reach. This prominent player is involved in various activities, such as collaborations with regional vendors as well as key players operating in the botulinum toxin market. The company has also successfully integrated small companies through mergers and acquisitions to build a strong supply chain network. The company has captured 75.3% of the global market share in 2018.
Ipsen Pharma and Galderma SA accounted for the second-largest market share of 10.3% in 2018. It operates in endocrinology, oncology, neurology, cognitive disorders, gastroenterology, and rheumatology areas. The company has a strong research and development unit which offers innovative products.
Merz Pharma GmbH & Co KGaA operates through the following segments, namely, neurology, over the counter (OTC) medicine, dietary supplements, and skincare products. The company accounted for 7% of the total botulinum toxin market share in 2018.
Other prominent players operating in the market are Daewoong Pharmaceutical Co., Ltd, US WorldMeds, LLC, Evolus, Inc., Hugel, Inc., and Medytox. The majority of the companies are working in collaboration with local players to distribute their products in the market. Moreover, companies such as Revance Therapeutics, Inc. are developing innovative products that are likely to hit the market in the next 3 to 5 years. After product approval of core products, Revance Therapeutics, Inc. is anticipated to capture the significant market share of the global botulinum toxin market.
Threat of New Entrants
The threat of new entrants is moderate to high in the global botulinum toxin market. Any manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. The botulinum toxin market is also characterized by a reasonable degree of brand loyalty towards brands such as Botox, where establishing a brand name is difficult for newcomers and small companies. However, the cost involved in R&D is comparatively high, which does not comfort the new entrants to enter the market easily. Recently, due to different cases related to horrific adverse events of botulinum toxin such as allergic reactions, muscle stiffness, nausea, and respiratory infections, regulatory authorities have made approvals stricter and started scrutinized checks for every product with more detail.
Additionally, the rising awareness regarding the aesthetic products and its benefits among the population pushes the current manufacturers to focus more on the R&D of innovative products with therapeutic use. Thus, the threat of new entrants in the market is moderate. Thus, the threat of new entrants remains moderate to high.
Bargaining Power of Suppliers
The suppliers in the global botulinum toxin market are the developers and manufacturers of botulinum toxin products. The existing key companies capture a significant share of the market and have the capability of influencing the cost of products. Another factor affecting the bargaining power of suppliers is the switching cost for buyers. Since there are a few options to choose from, this gives a low level of leverage to the buyers to switch.
Furthermore, many companies are focused on entering the global market, which increases competition. However, developing countries in the Asia-Pacific region consist of a large number of local players that offer botulinum toxin products at a reasonable rate. This leads to the high bargaining power of suppliers, and the profit potential of the global botulinum toxin market is increased. Thus, the threat of new entrants remains moderate.
Threat of Substitutes
The threat of substitutes in the global botulinum toxin market is moderate to high. Buyer propensity to substitute is also a factor that should be given importance. The emerging trend of usage of hyaluronic acid can hamper the growth of the market. Various substitutes are available in the market, which can replace botulinum toxin in cosmetic procedures. However, quality and trust issues for products provided by new players, and excellent sales support provided by existing players may restrict the threat of substitutes to an extent. Thus, the threat of substitutes tends to be moderate to high.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global botulinum toxin market. The market has a large number of buyers. The buyers are moderately inclined towards branded botulinum toxin products manufactured by established players. There is a limited number of suppliers present in the market to cater to the needs of customers. Moreover, buyers can exert moderate pressure on the manufacturers to provide high-quality products with fewer side effects. Hence, with the high quality of products provided by the botulinum toxin manufacturers, the bargaining power of suppliers tends to be moderate.
Intensity of Rivalry
The degree of competition in the global botulinum toxin market is moderate to high. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. Aesthetic products and neurotoxin manufacturers are trying to develop less expensive products to make them more affordable in developing markets. To overcome the competition, players are engaged in developing a process to lower their manufacturing costs. Moreover, the players are also developing advanced products for differentiating their brand from their competitors.
Market estimates by geography (2025)
InsightAmericas leads with $4.48B by 2025, while Asia Pacific is projected to grow fastest at a 11.2% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Asia Pacific | $771.09M | $1.32B | $2.01B | 11.2% | 21% |
| Americas | $1.88B | $3.08B | $4.48B | 10.1% | 47% |
| Europe | $970.57M | $1.63B | $2.43B | 10.7% | 26% |
| Middle East and Africa | $214.83M | $357.40M | $527.22M | 10.5% | 6% |
| Total | $3.84B | $6.39B | $9.44B | 10.5% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$9.44B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Botunilim Toxin Type A | $9.08B | 10.5% | 96% |
| Botunilim Toxin Type B | $360.16M | 11.0% | 4% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Botulinum Toxin Market covering market dynamics, competitive landscape, and strategic outlook.
The Botulinum Toxin Market market is projected to reach $9.44B by 2025, growing at 10.5% CAGR. The Botunilim Toxin Type A segment holds the largest share.
Botulinum toxin is known as one of the most poisonous biological substance. It is a neurotoxin produced by the bacterium Clostridium botulinum. There are seven distinct forms of botulinum toxin, types A–G. Four of these (types A, B, E, and rarely F) cause human botulism. Types C, D and E cause illness in other mammals, birds and fish.
A study was published in journal Transactions of the American Ophthalmological Society, demonstrating the effectiveness of botulinum toxin type A for the management of strabismus in humans. Botulinum toxins play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia, hemifacial spasm, and various spastic movement disorders, headaches, hypersalivation, and hyperhidrosis, among others. In 2002, the US FDA approved the use of Botox (Botulinum toxin A) for the cosmetic purpose of temporarily reducing glabellar forehead frown lines.
The rising cases of spasticity, cervical dystonia and chronic migraine, growing demand for facial aesthetics, and increasing product launches and approvals by key players are expected to drive the growth of the botulinum toxin market. However, adverse effects associated with botulinum toxin and poor reimbursement policies are expected to hamper the market growth.
The use of botulinum toxin for cosmetic purposes has skyrocketed in past years, especially after the approval of botulinum toxin type A for the treatment of glabellar lines. The use of Botox was mainly confined to the correct muscles of facial expression over the upper one-third of the face. Currently, its application ranges from the correction of lines, wrinkles on the face, chin, neck, chest, depressor anguli oris, nasolabial folds, mentalis, medial, and lateral brow lifts to lessen shadows and maintain smooth lines of jaw and cheeks. Moreover, Botulinum neurotoxin is a major therapeutic agent licensed in neurological indications such as dystonia and spasticity.
Currently, all the commercially available botulinum toxin products are manufactured using native Clostridium botulinum as the production organism, although some companies are exploring the use of recombinant expression using Escherichia coli. This would allow a standardized and safer manufacturing process for botulinum toxin type A and other serotypes and genetically modified versions of the neurotoxin. The modified and recombinant toxins would expand the therapeutic applications of botulinum toxins. This, in turn, would create demand for botulinum toxin products in the coming years.
In addition to this, major companies are entering the market for the development of new products. For instance, Revance Therapeutics, Inc., one of the leading healthcare companies, has many Phase II and Phase III products in the pipeline, such as DAXI Neuroscience, for the treatment of planter fasciitis in Phase II and DAXI Aesthetics for treatment of glabellar lines which has passed Phase III. This increase in the number of clinical trials results in the subsequent launch of new products in the market in the upcoming years and thereby is expected to boost the market growth.
Clostridium botulinum, an anaerobic gram-positive bacterium, produces seven different types of toxins from A to G. In clinical practice, only toxin A (Botox, Vistabex, Dysport) and toxin B (Neurobloc) are used. Botulinum toxin vials must be kept refrigerated according to the manufacturers’ indications. They must be reconstituted with physiological solutions and used within 4 to 5 hours. The medication needs to be diluted in physiological solution, as high dilutions might facilitate wider diffusion with consequent increased risks of adverse reactions and engagement of adjoining muscles.
While treating palmar hyperhidrosis, a temporary reduction of prehension strength might occur. High dosage of botulinum toxin (viz. 300 U Botox, 1,050 U Dysport) have reported transitory generalized asthenia and accommodation disturbances. The toxin used for aesthetic treatments is indicated only for glabellar wrinkles. The usage of the toxin for any other aesthetic reasons in very delicate injections sites like around the eyes, on the forehead, around the lips and on the neck is off the label and can expose patients to severe risks. For instance, botulinum administration around the mouth can compromise the mastication muscles function and create speech impairments. Moreover, palpebral ptosis, focal facial paralysis, paresthesia and numbness, asthenia, muscular weakness, dysphagia and visual disturbances are other side effects associated with botulinum toxin. This is expected to hamper the growth of the market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Botulinum Toxin Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Company Headquarters: Paris, France Founded: 1929 Workforce: ~ 5,400+ Company Working: Ipsen Pharma is a global pharmaceutical company operating in two segments, namely, specialty care and consumer healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rare disease areas. In the neuroscience segment, the company provides products for the treatment of cervical dystonia, adult spasticity, blepharospasm, hemifacial spasm, hyperhidrosis, and pediatric lower limb spasticity. Ipsen Pharma operates as a subsidiary of Mayroy S.A. The company has R&D centers and manufacturing sites located in China, France, Ireland, the UK, and the US. Ipsen Pharma is present in more than 115 countries and has a direct presence through corporates offices in around 35 countries across the globe.
Company Headquarters: Dublin, Ireland Founded: 2013 Workforce: ~16,900 Company Working: Allergan is a leading global pharmaceutical company. The company is engaged in the manufacturing and commercialization of hyaluronic acid for medical products, devices, biologics, and surgical products for patients across the world. It operates through three business segments, namely US Specialized Therapeutics, US General Medicine, and International. The company sells its products primarily to the retailers and distributors including food store chains and national retail drug. The prime customers are hospitals, clinics, and government agencies as well as managed healthcare providers, such as health maintenance organizations and other institutions. The company has operations in 100 countries. The US and Canada account for around 10% of the company’s revenue. The three prominent customers of the company are McKesson Corporation, which accounted for around 25% of the sales revenue; Cardinal Health, Inc with 23%; and AmerisourceBergen Corporation with 22% in 2018. In addition, the company has development and manufacturing centers of raw materials, intermediate ingredients, and active pharmaceutical ingredients. Its manufacturing plants are located in Ireland, the US, Brazil, Belgium, France, and Costa Rica.
Established in 1981 and headquarters in Lausanne, Switzerland. Galderma is one of the big names of the pharmaceutical industry in dermatology, over the past three decades galderma key area of focus is to provide innovative solutions in the field of dermatology, which consists of acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and other various fields in skin care. Currently Galderma is a global leader in dermatology and has strategic partnerships with brands like Soolantra, Tri-Luma, Loceryl, BenzacEpiduo, Oracea, Differin, Mirvaso, Cetaphil, Excipial, Daylong, Restylane, Emervel and many other brands. Presently galderma is operating in over 80+ countries, providing patients with skin care needs and has an employee work force of over 6000 employees. The company has worldwide network of distributers and 34 wholly-owned affiliates.
US WORLDMEDS — Healthcare
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
